Literature DB >> 14557486

Reduced expression of immunoreactive beta2-adrenergic receptor protein in human myometrium with labor.

Boonsri Chanrachakul1, Balwir Matharoo-Ball, Anita Turner, Graham Robinson, Fiona Broughton-Pipkin, Sabaratnam Arulkumaran, Raheela N Khan.   

Abstract

A considerable body of evidence exists suggesting that the beta(2)-adrenergic receptor (beta(2)-AR) mediates uterine relaxation. However, little information exists on the localization, distribution, or expression of beta(2)-ARs in the human myometrium during the nonpregnant to labor transition. We have used immunochemical methods to investigate beta(2)-AR localization and expression in the nonpregnant, term pregnant, and term parturient uterus. Myometrial biopsies were obtained from 1) nonpregnant, menstruating women undergoing hysterectomy; 2) singleton term pregnant women undergoing elective cesarean section before the onset of labor; or 3) singleton term pregnant women undergoing emergency cesarean section after spontaneous labor. Tissues were processed for immunohistochemistry, immunofluorescence, and Western blotting and a primary polyclonal antibody specific to the human beta(2)-AR to identify immunoreactive myometrial beta(2)-AR. Protein levels were subsequently quantified by densitometry relative to rat brain protein. Immunohistochemistry and immunofluorescence demonstrated the presence of beta(2)-AR predominantly at the plasma membrane and also in the cytosol of myometrial cells. A 2-fold decrease in protein levels of the beta(2)-AR was apparent in the myometrium of labor compared with that of nonpregnant and pregnant nonlaboring women (P < 0.05). These results demonstrate that down-regulation of beta(2)-AR protein with labor may constitute a contributory mechanism by which uterine quiescence is removed at term.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557486     DOI: 10.1210/jc.2003-030692

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Comparison effect of oral propranolol and oxytocin versus oxytocin only on induction of labour in nulliparous women (a double blind randomized trial).

Authors:  Ashraf Direkvand Moghadam; Molouk Jaafarpour; Ali Khani
Journal:  J Clin Diagn Res       Date:  2013-11-10

2.  Expression of scaffolding, signalling and contractile-filament proteins in human myometria: effects of pregnancy and labour.

Authors:  M Riley; P N Baker; R M Tribe; M J Taggart
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

3.  Depletion of membrane cholesterol eliminates the Ca2+-activated component of outward potassium current and decreases membrane capacitance in rat uterine myocytes.

Authors:  A Shmygol; K Noble; Susan Wray
Journal:  J Physiol       Date:  2007-03-01       Impact factor: 5.182

4.  The effect of oral propranolol plus oxytocin versus oxytocin only on the process and outcome of labor: A double-blind randomized trial.

Authors:  Ashraf Direkvand-Moghadam; Molouk Jaafarpour; Ali Khani; Safoura Taheri; Ali Delpisheh
Journal:  Iran J Nurs Midwifery Res       Date:  2014-09

5.  Polymorphism of the ADRB2 Rs1042713 Gene is not Associated with Spontaneous Preterm Birth: Analyses in a Slovenian Sample and Meta Analysis.

Authors:  Peterlin A; Maver A; Jan Z; Lovrecic L; Tul N; Peterlin B
Journal:  Balkan J Med Genet       Date:  2017-12-29       Impact factor: 0.519

6.  Expression of renin-angiotensin system components in the early bovine embryo.

Authors:  Wioletta Pijacka; Morag G Hunter; Fiona Broughton Pipkin; Martin R Luck
Journal:  Endocr Connect       Date:  2012-06-21       Impact factor: 3.335

Review 7.  Is the beta3-adrenoceptor (ADRB3) a potential target for uterorelaxant drugs?

Authors:  Marc Bardou; Céline Rouget; Michèle Breuiller-Fouché; Catherine Loustalot; Emmanuel Naline; Paul Sagot; René Frydman; Esteban J Morcillo; Charles Advenier; Marie-Josèphe Leroy; John J Morrison
Journal:  BMC Pregnancy Childbirth       Date:  2007-06-01       Impact factor: 3.007

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.